已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Rationale and design of ‘discontinuing statins in multimorbid older adults without cardiovascular disease (STREAM)’: study protocol of a randomised non-inferiority clinical trial

医学 中止 临床终点 随机对照试验 物理疗法 生活质量(医疗保健) 他汀类 人口 预期寿命 临床试验 意向治疗分析 冲程(发动机) 心肌梗塞 内科学 机械工程 环境卫生 工程类 护理部
作者
Philipp Stefan Aebi,Luise Adam,Moa Lina Haller,Julia B. Bardoczi,Bariş Gencer,Fabrice Bonnet,Jürg Hans Beer,Sebastian Carballo,Mirjam Christ‐Crain,Martin Feller,Luca Gabutti,Alan G. Haynes,Elisavet Moutzouri,Patricia Orializ Chocano-Bedoya,Stefano Bassetti,Robert Escher,Martin Egger,Rosalinde K. E. Poortvliet,Philipp Schüetz,Sven Trelle
出处
期刊:BMJ Open [BMJ]
卷期号:15 (5): e093833-e093833 被引量:4
标识
DOI:10.1136/bmjopen-2024-093833
摘要

INTRODUCTION: Statins are among the most widely used drugs. While they are effective for primary and secondary prevention of cardiovascular (CV) disease in middle-aged subjects, their benefits for prevention in older adults (aged ≥70 years) without CV disease are uncertain, particularly for those with multimorbidity. Statin side effects and drug interactions are common in older patients and may negatively impact quality of life. To date, the only randomised controlled trial (RCT) investigating statin discontinuation in older adults has demonstrated no difference in survival but did note a small improvement in quality of life for those who discontinued statins. However, this trial exclusively enrolled patients with a life expectancy <1 year. Therefore, the present RCT aims to assess the safety and potential benefits of statin discontinuation in primary prevention for the ever-growing population of multimorbid older adults. METHODS AND ANALYSIS: This study is a multicentre, randomised, non-inferiority trial conducted in both inpatient and outpatient settings in Switzerland, France and the Netherlands, targeting patients using statins for primary prevention. 1800 participants are randomly assigned 1:1 to either discontinue (intervention arm) or continue (control arm) statin therapy. The primary objective is to compare the primary composite endpoint of major CV events (non-fatal myocardial infarction or non-fatal ischaemic stroke) and all-cause death between the control and intervention groups over a follow-up duration of up to 48 months. We hypothesise that discontinuing statins does not result in shorter event-free survival, with a non-inferiority margin set at 5.2 weeks over a 2-year observation period. Secondary objectives are to compare patient-centred outcomes (health-related quality of life, muscle pain symptoms, falls and sarcopenia) and all-cause death, non-CV death, major CV events and coronary and peripheral artery revascularisation. The study is open-labelled, with blinded outcome adjudication of the primary endpoints. ETHICS AND DISSEMINATION: The trial protocol has received approval from the local ethics committees in Switzerland, France and the Netherlands. Results will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov: NCT05178420; BASEC (Swiss Ethics Commission): 2021-01513; FOPH (Swiss national portal): SNCTP000005172; Netherlands Trial Register: NL83907.058.23; France Trial Register: 22.04747.000158- IDRCB 2022-A02481-42.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
思源的应助被七七采纳,获得10
1秒前
2秒前
2秒前
2秒前
cxy完成签到,获得积分10
4秒前
李_完成签到,获得积分10
4秒前
Zhixia发布了新的文献求助10
5秒前
ding的应助被聆听采纳,获得10
5秒前
专注凝蝶发布了新的文献求助10
5秒前
盒子发布了新的文献求助10
5秒前
刘勇完成签到,获得积分10
6秒前
6秒前
王涛发布了新的文献求助10
6秒前
7秒前
缺口口发布了新的文献求助10
7秒前
anian发布了新的文献求助10
7秒前
刘勇发布了新的文献求助10
9秒前
小马甲的应助被高大橙采纳,获得10
9秒前
10秒前
酷波er的应助被一期一会采纳,获得30
10秒前
xiao完成签到,获得积分10
10秒前
yangqisen发布了新的文献求助10
11秒前
充电宝的应助被Ruhanna采纳,获得10
12秒前
星矢一道完成签到 ,获得积分10
13秒前
zhang完成签到,获得积分10
13秒前
13秒前
飘落的樱花完成签到,获得积分10
14秒前
edisonzz发布了新的文献求助10
15秒前
15秒前
15秒前
chen发布了新的文献求助10
16秒前
小丹小丹完成签到 ,获得积分10
16秒前
anian完成签到,获得积分10
17秒前
情怀的应助被科研通管家采纳,获得10
18秒前
思源的应助被科研通管家采纳,获得10
18秒前
DW的应助被科研通管家采纳,获得10
18秒前
perway完成签到,获得积分10
18秒前
Owen的应助被科研通管家采纳,获得30
18秒前
DW的应助被科研通管家采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643